Technical brief |

MSF analysis of Gilead Hepatitis C license

Médecins Sans Frontières/ Doctors Without Borders (MSF) plans to start treating people infected with hepatitis C virus in nine countries.

This requires affordable access to direct acting antiviral treatments, including those first registered by Gilead Sciences, and is looking for quality-assured generic versions that can help scale up treatment. However, Gilead’s voluntary license restricts access to affordable generic versions for millions of people with HCV in middle-income countries.

Read our analysis and key reccommendations on Gilead's voluntary license.

MSF analysis of Gilead Hepatitis C license